> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period Determination for Intercept Plasma Device
- URL: https://www.fdaweb.com/regulatory-review-period-determination-for-intercept-plasma-device/
- Published: 2017-07-11T12:00:00.000Z
- Updated: 2026-09-14T22:33:30.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139101

*Federal Register* notice: FDA has determined that the regulatory review period for Cerus Corp.’s Intercept Blood System For Plasma is 6,497 days, which includes 6,114 days during the testing phase and 383 days during the approval phase. The determination was made pursuant to applications submitted to the U.S. Patent and Trademark Office for the extension of a patent that claims the medical device. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-07-11/pdf/2017-14454.pdf?ref=fdaweb.com).